News | Radiopharmaceuticals and Tracers | April 11, 2017

IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium

New company will provide diagnostic and therapeutic solutions from 21 manufacturing centers worldwide

IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium

April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt Nuclear Medicine LLC to form the new company Curium.

The new entity delivers diagnostic and therapeutic solutions to over 14 million people from a global network of 21 manufacturing centers; this includes one molybdenum facility, three large single-photon emission computed tomography (SPECT) facilities, and close to 40 SPECT and positron emission tomography (PET) radiopharmacies.

IBA Molecular acquired the Nuclear Medicine portion of Mallinckrodt in January, completing a process that began in August 2016. The acquisition included Mallinckrodt’s manufacturing operations in the United States and the Netherlands, according to the St. Louis Business Journal.

For more information: www.curiumpharma.com


Additional Content

Feature | Nuclear Imaging

Cardiac PET/CT represents a major advancement in cardiovascular diagnostics, offering significant clinical and ...

Home November 12, 2025
Home
News | Nuclear Imaging

August 3, 2023 — The cardiovascular polypill, developed by the Spanish National Centre for Cardiovascular Research (CNIC ...

Home August 03, 2023
Home
News | Nuclear Imaging

January 5, 2023 — A new study has determined that approximately three percent of all bone scan patients have markers of ...

Home January 05, 2023
Home
News | Nuclear Imaging

April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...

Home April 13, 2022
Home
Videos | Nuclear Imaging

American Society of Nuclear Cardiology (ASNC) President Dennis Calnon, M.D., MASNC, FASE, FSCCT, director of cardiac ...

Home February 01, 2022
Home
Subscribe Now